LNTH - Lantheus Q3 2023 Earnings Preview
2023-11-01 13:02:03 ET
More on Lantheus
- Lantheus: Fast-Growing Radiotherapeutics Specialist Can Benefit From Lilly's POINT Biopharma Takeover
- Lantheus: Growth Well Priced In, Profitability Next Hurdle (Rating Downgrade)
- Lantheus: Not Quite Ready To Take The Plunge
- Eli Lilly to acquire Point Biopharma in $1.4B deal (update)
- Lantheus to discontinue radiotherapy Azedra
For further details see:
Lantheus Q3 2023 Earnings Preview